Annandale Capital, LLC Uro Gen Pharma Ltd. Transaction History
Annandale Capital, LLC
- $631 Million
- Q4 2024
A detailed history of Annandale Capital, LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Annandale Capital, LLC holds 75,552 shares of URGN stock, worth $847,693. This represents 0.13% of its overall portfolio holdings.
Number of Shares
75,552
Previous 75,552
-0.0%
Holding current value
$847,693
Previous $960,000
16.15%
% of portfolio
0.13%
Previous 0.13%
Shares
5 transactions
Others Institutions Holding URGN
# of Institutions
136Shares Held
36MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$43 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$32.9 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$25.8 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$24.6 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$19.6 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $255M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...